3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
2
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Multiple Myeloma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Pain, Postoperative
2
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Pain
1
Ovarian Neoplasms
1
Lymphoma, Follicular
1
Lymphoma
1
Lung Neoplasms
1
Kidney Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Burkitt Lymphoma
1
Interventions
Cyclophosphamide
29
blinatumomab
19
Vincristine
16
Specimen Handling
13
Methotrexate
13
Dexamethasone
13
fludarabine
12
Prednisone
11
Cytarabine
11
Biopsy
11
Doxorubicin
9
Asparaginase
9
Rituximab
8
Mercaptopurine
8
Inotuzumab Ozogamicin
8
merphos
7
Spinal Puncture
7
N,N-dicyclohexyl-isoborneol-10-sulfonamide
7
Magnetic Resonance Spectroscopy
7
venetoclax
6
prednylidene
6
dexamethasone acetate
6
dexamethasone 21-phosphate
6
deltacortene
6
azathiopurine
6
auricularum
6
Etoposide
6
Daunorubicin
6
Calcium Dobesilate
6
pegaspargase
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Burkitt Lymphoma
×
Acetaminophen
×
Clear all
NCT07570173
2026-06-05
MK-1045-005
Merck Sharp & Dohme LLC
Phase 2/3
Recruiting
340 enrolled